{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:35:10Z","timestamp":1790768110696,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T00:00:00Z","timestamp":1677196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T00:00:00Z","timestamp":1677196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NCI NIH","award":["R01 CA116477"],"award-info":[{"award-number":["R01 CA116477"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Alpha-emitter radiopharmaceutical therapy (\u03b1RPT) has shown promising outcomes in metastatic disease. However, the short range of the alpha particles necessitates dosimetry on a near-cellular spatial scale. Current knowledge on cellular dosimetry is primarily based on in vitro experiments using cell monolayers. The goal of such experiments is to establish cell sensitivity to absorbed dose (AD). However, AD cannot be measured directly and needs to be modeled. Current models, often idealize cells as spheroids in a regular grid (geometric model), simplify binding kinetics and ignore the stochastic nature of radioactive decay. It is unclear what the impact of such simplifications is, but oversimplification results in inaccurate and non-generalizable results, which hampers the rigorous study of the underlying radiobiology.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We systematically mapped out 3D cell geometries, clustering behavior, agent binding, internalization, and subcellular trafficking kinetics for a large cohort of live cells under representative experimental conditions using confocal microscopy. This allowed for realistic Monte Carlo-based (micro)dosimetry. Experimentally established surviving fractions of the HER2\u2009+\u2009breast cancer cell line treated with a <jats:sup>212<\/jats:sup>Pb-labelled anti-HER2 conjugate or external beam radiotherapy, anchored a rigorous statistical approach to cell sensitivity and relative biological effectiveness (RBE) estimation. All outcomes were compared to a reference geometric model, which allowed us to determine which aspects are crucial model components for the proper study of the underlying radiobiology.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total,\u00a0567\u00a0cells were measured up to 26\u00a0h post-incubation. Realistic cell clustering had a large (2x), and cell geometry a small (16.4% difference) impact on AD, compared to the geometric model. Microdosimetry revealed that more than half of the cells do not receive any dose for most of the tested conditions, greatly impacting cell sensitivity estimates. Including these stochastic effects in the model, resulted in significantly more accurate predictions of surviving fraction and RBE (permutation test; p\u2009&lt;\u2009.01).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This comprehensive integration of the biological and physical aspects resulted in a more accurate method of cell survival modelling in \u03b1RPT experiments. Specifically, including realistic stochastic radiation effects and cell clustering behavior is crucial to obtaining generalizable radiobiological parameters.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12967-023-03991-1","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T07:02:53Z","timestamp":1677222173000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Large-scale in vitro microdosimetry via live cell microscopy imaging: implications for radiosensitivity and RBE evaluations in alpha-emitter radiopharmaceutical therapy"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7056-3229","authenticated-orcid":false,"given":"Remco","family":"Bastiaannet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Liatsou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"F Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Sgouros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,24]]},"reference":[{"key":"3991_CR1","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/jamaoncol.2016.4166","volume":"3","author":"S Salas-Vega","year":"2017","unstructured":"Salas-Vega S, Iliopoulos O, Mossialos E. Assessment of overall survival, quality of life, and safety benefits associated with new cancer medicines. JAMA Oncol. 2017;3:382.","journal-title":"JAMA Oncol"},{"key":"3991_CR2","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S1470-2045(19)30456-5","volume":"20","author":"M Arnold","year":"2019","unstructured":"Arnold M, Rutherford MJ, Bardot A, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995\u20132014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol. 2019;20:1493\u2013505.","journal-title":"Lancet Oncol"},{"key":"3991_CR3","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","volume":"19","author":"G Sgouros","year":"2020","unstructured":"Sgouros G, Bodei L, McDevitt MR, Nedrow JR. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020;19:589\u2013608.","journal-title":"Nat Rev Drug Discov"},{"key":"3991_CR4","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, Kopka K, Apostolidis C, Haberkorn U, Morgenstern A. 225Ac-PSMA-617 for PSMA-targeted a-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57:1941\u20134.","journal-title":"J Nucl Med"},{"key":"3991_CR5","doi-asserted-by":"publisher","first-page":"5479","DOI":"10.1158\/0008-5472.CAN-19-2806","volume":"79","author":"G Sgouros","year":"2019","unstructured":"Sgouros G. \u03b1-Particle-emitter radiopharmaceutical therapy: Resistance is futile. Cancer Res. 2019;79:5479\u201381.","journal-title":"Cancer Res"},{"key":"3991_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.semradonc.2020.07.008","volume":"31","author":"SA Graves","year":"2021","unstructured":"Graves SA, Hobbs RF. Dosimetry for optimized, personalized radiopharmaceutical therapy. Semin Radiat Oncol. 2021;31:37\u201344.","journal-title":"Semin Radiat Oncol"},{"key":"3991_CR7","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.ijrobp.2020.08.035","volume":"109","author":"St. James S, Bednarz B, Benedict S,","year":"2021","unstructured":"St. James S, Bednarz B, Benedict S, et al. Current status of radiopharmaceutical therapy. Int J Radiat Oncol Biol Phys. 2021;109:891\u2013901.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3991_CR8","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.2967\/jnumed.113.131037","volume":"55","author":"B Vaziri","year":"2014","unstructured":"Vaziri B, Wu H, Dhawan AP, et al. MIRD pamphlet No. 25: MIRDcell V2.0 software tool for dosimetric analysis of biologic response of multicellular populations. J Nucl Med. 2014;55:1557\u201364.","journal-title":"J Nucl Med"},{"key":"3991_CR9","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.nimb.2015.11.008","volume":"366","author":"FX Arnaud","year":"2016","unstructured":"Arnaud FX, Paillas S, Pouget JP, Incerti S, Bardi\u00e8s M, Bordage MC. Complex cell geometry and sources distribution model for Monte Carlo single cell dosimetry with iodine 125 radioimmunotherapy. Nucl Instruments Methods Phys Res Sect B Beam Interact with Mater Atoms. 2016;366:227\u201333.","journal-title":"Nucl Instruments Methods Phys Res Sect B Beam Interact with Mater Atoms"},{"key":"3991_CR10","doi-asserted-by":"publisher","DOI":"10.1088\/2057-1976\/abf29f","author":"FDC Guerra Liberal","year":"2021","unstructured":"Guerra Liberal FDC, McMahon SJ, Prise KM. TOPAS a tool to evaluate the impact of cell geometry and radionuclide on alpha particle therapy. Biomed Phys Eng Express. 2021. https:\/\/doi.org\/10.1088\/2057-1976\/abf29f.","journal-title":"Biomed Phys Eng Express"},{"key":"3991_CR11","doi-asserted-by":"publisher","first-page":"109509","DOI":"10.1016\/j.apradiso.2020.109509","volume":"168","author":"W Tang","year":"2021","unstructured":"Tang W, Tang B, Li X, Wang Y, Li Z, Gao Y, Gao H, Yan C, Sun L. Cellular S-value evaluation based on real human cell models using the GATE MC package. Appl Radiat Isot. 2021;168:109509.","journal-title":"Appl Radiat Isot"},{"key":"3991_CR12","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1118\/1.3462971","volume":"37","author":"KM Langen","year":"2010","unstructured":"Langen KM, Papanikolaou N, Balog J, Crilly R, Followill D, Goddu SM, Grant W, Olivera G, Ramsey CR, Shi C. QA for helical tomotherapy: report of the AAPM Task Group 148. Med Phys. 2010;37:4817.","journal-title":"Med Phys"},{"key":"3991_CR13","first-page":"521","volume":"35","author":"SM Goddu","year":"1994","unstructured":"Goddu SM, Rao DV, Howell RW. Multicellular dosimetry for micrometastases: dependence of self-dose versus cross-dose to cell nuclei on type and energy of radiation and subcellular distribution of radionuclides. J Nucl Med. 1994;35:521\u201330.","journal-title":"J Nucl Med"},{"key":"3991_CR14","doi-asserted-by":"publisher","first-page":"250","DOI":"10.2967\/jnumed.117.207308","volume":"60","author":"N Falzone","year":"2018","unstructured":"Falzone N, Lee BQ, Able S, Malcolm J, Terry S, Alayed Y, Vallis KA. Targeting micrometastases: the effect of heterogeneous radionuclide distribution on tumor control probability. J Nucl Med. 2018;60:250.","journal-title":"J Nucl Med"},{"key":"3991_CR15","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/mp.13969","volume":"47","author":"AM Frelin-Labalme","year":"2020","unstructured":"Frelin-Labalme AM, Roger T, Falzone N, Quan Lee B, Sibson NR, Vallis KA, Bernaudin M, Valable S, Corroyer-Dulmont A. Radionuclide spatial distribution and dose deposition for in vitro assessments of 212Pb-\u03b1VCAM-1 targeted alpha therapy. Med Phys. 2020;47:1317\u201326.","journal-title":"Med Phys"},{"key":"3991_CR16","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2307\/3578212","volume":"133","author":"MR Raju","year":"1993","unstructured":"Raju MR, Eisen Y, Carpenter S, Jarrett K, Harvey WF. Radiobiology of alpha particles. IV. Cell inactivation by alpha particles of energies 0.4-3.5 MeV. Radiat Res. 1993;133:289\u201396.","journal-title":"Radiat Res"},{"key":"3991_CR17","doi-asserted-by":"publisher","first-page":"204","DOI":"10.2307\/3578139","volume":"128","author":"MR Raju","year":"1991","unstructured":"Raju MR, Eisen Y, Carpenter S, Inkret WC. Radiobiology of alpha particles. III. Cell inactivation by alpha-particle traversals of the cell nucleus. Radiat Res. 1991;128:204\u20139.","journal-title":"Radiat Res"},{"key":"3991_CR18","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/153212","author":"CY Huang","year":"2012","unstructured":"Huang CY, Guatelli S, Oborn BM, Allen BJ. Microdosimetry for targeted alpha therapy of cancer. Comput Math Methods Med. 2012. https:\/\/doi.org\/10.1155\/2012\/153212.","journal-title":"Comput Math Methods Med"},{"key":"3991_CR19","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.rpor.2014.10.006","volume":"21","author":"GA Santa Cruz","year":"2016","unstructured":"Santa Cruz GA. Microdosimetry: principles and applications. Reports Pract Oncol Radiother. 2016;21:135\u20139.","journal-title":"Reports Pract Oncol Radiother"},{"key":"3991_CR20","first-page":"1923","volume":"38","author":"JC Roeske","year":"1997","unstructured":"Roeske JC, Stinchcomb TG. Dosimetric framework for therapeutic alpha-particle emitters. J Nucl Med. 1997;38:1923\u20139.","journal-title":"J Nucl Med"},{"key":"3991_CR21","doi-asserted-by":"publisher","first-page":"266","DOI":"10.2174\/1874471011104030266","volume":"4","author":"N Chouin","year":"2012","unstructured":"Chouin N, Bardies M. Alpha-Particle Microdosimetry. Curr Radiopharm. 2012;4:266\u201380.","journal-title":"Curr Radiopharm"},{"key":"3991_CR22","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1080\/09553002.2022.2033341","volume":"98","author":"I Liatsou","year":"2022","unstructured":"Liatsou I, Yu J, Bastiaannet R, Li Z, Hobbs RF, Torgue J, Sgouros G. 212 Pb-conjugated anti-rat HER2\/ neu antibody against a neu -N derived murine mammary carcinoma cell line: cell kill and RBE in vitro. Int J Radiat Biol. 2022;98:1452.","journal-title":"Int J Radiat Biol"},{"key":"3991_CR23","first-page":"880","volume":"61","author":"RT Reilly","year":"2001","unstructured":"Reilly RT, Machiels JPH, Emens LA, Ercolini AM, Okoye FI, Lei RY, Weintraub D, Jaffee EM. The collaboration of both humoral and cellular HER-2\/neu-targeted immune responses is required for the complete eradication of HER-2\/neu-expressing tumors. Cancer Res. 2001;61:880\u20133.","journal-title":"Cancer Res"},{"key":"3991_CR24","first-page":"3569","volume":"60","author":"RT Reilly","year":"2000","unstructured":"Reilly RT, Gottlieb MBC, Ercolini AM, Machiels JPH, Kane CE, Okoye FI, Muller WJ, Dixon KH, Jaffee EM. HER-2\/neu is a tumor rejection target in tolerized HER-2\/neu transgenic mice. Cancer Res. 2000;60:3569\u201376.","journal-title":"Cancer Res"},{"key":"3991_CR25","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1109\/TPAMI.2013.106","volume":"36","author":"P Marquez-Neila","year":"2014","unstructured":"Marquez-Neila P, Baumela L, Alvarez L. A morphological approach to curvature-based evolution of curves and surfaces. IEEE Trans Pattern Anal Mach Intell. 2014;36:2\u201317.","journal-title":"IEEE Trans Pattern Anal Mach Intell"},{"key":"3991_CR26","doi-asserted-by":"crossref","unstructured":"Marstal K, Berendsen F, Staring M, Klein S. SimpleElastix: A User-Friendly, Multi-lingual Library for Medical Image Registration. IEEE Comput Soc Conf Comput Vis Pattern Recognit Work. 2016;574\u2013582.","DOI":"10.1109\/CVPRW.2016.78"},{"key":"3991_CR27","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1109\/TSMC.1979.4310076","volume":"9","author":"N Otsu","year":"1979","unstructured":"Otsu N. A threshold selection method from gray-level histograms. IEEE Trans Syst Man Cybern. 1979;9:62\u20136.","journal-title":"IEEE Trans Syst Man Cybern"},{"key":"3991_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/ph12040177","author":"T Deno\u00ebl","year":"2019","unstructured":"Deno\u00ebl T, Pedrelli L, Pantaleo G, Prior JO. A robust method for assaying the immunoreactive fraction in nonequilibrium systems. Pharmaceuticals. 2019. https:\/\/doi.org\/10.3390\/ph12040177.","journal-title":"Pharmaceuticals"},{"key":"3991_CR29","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.nima.2016.06.125","volume":"835","author":"J Allison","year":"2016","unstructured":"Allison J, Amako K, Apostolakis J, et al. Recent developments in GEANT4. Nucl Instruments Methods Phys Res Sect A Accel Spectromet Detect Assoc Equip. 2016;835:186\u2013225.","journal-title":"Nucl Instruments Methods Phys Res Sect A Accel Spectromet Detect Assoc Equip"},{"key":"3991_CR30","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s13246-012-0159-8","volume":"35","author":"CM Poole","year":"2012","unstructured":"Poole CM, Cornelius I, Trapp JV, Langton CM. A CAD interface for GEANT4. Australas Phys Eng Sci Med. 2012;35:329\u201334.","journal-title":"Australas Phys Eng Sci Med"},{"key":"3991_CR31","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1080\/09553002.2020.1838659","volume":"96","author":"J Yu","year":"2020","unstructured":"Yu J, Lu R, Nedrow JR, Sgouros G. Response of breast cancer carcinoma spheroids to combination therapy with radiation and DNA-PK inhibitor: growth arrest without a change in \u03b1\/\u03b2 ratio. Int J Radiat Biol. 2020;96:1534\u201340.","journal-title":"Int J Radiat Biol"},{"key":"3991_CR32","first-page":"327","volume":"48","author":"Y Kvinnsland","year":"2007","unstructured":"Kvinnsland Y, Stokke T, Aurlien E. Log normal distribution of cellular uptake of radioactivity. J Nucl Med. 2007;48:327.","journal-title":"J Nucl Med"},{"key":"3991_CR33","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1667\/0033-7587(2001)155[0288:RWAPEM]2.0.CO;2","volume":"155","author":"Y Kvinnsland","year":"2001","unstructured":"Kvinnsland Y, Stokke T, Aurlien E. Radioimmunotherapy with alpha-particle emitters: microdosimetry of cells with a heterogeneous antigen expression and with various diameters of cells and nuclei. Radiat Res. 2001;155:288\u201396.","journal-title":"Radiat Res"},{"key":"3991_CR34","first-page":"1049","volume":"47","author":"PVSV Neti","year":"2006","unstructured":"Neti PVSV, Howell RW. Log normal distribution of cellular uptake of radioactivity: implications for biologic responses to radiopharmaceuticals. J Nucl Med. 2006;47:1049\u201358.","journal-title":"J Nucl Med"},{"key":"3991_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmed.2021.692436","volume":"8","author":"JP Pouget","year":"2021","unstructured":"Pouget JP, Constanzo J. Revisiting the radiobiology of targeted alpha therapy. Front Med. 2021;8:1\u201311.","journal-title":"Front Med"},{"key":"3991_CR36","doi-asserted-by":"publisher","first-page":"11671","DOI":"10.1038\/s41598-019-48298-8","volume":"9","author":"RM de Kruijff","year":"2019","unstructured":"de Kruijff RM, Raav\u00e9 R, Kip A, Molkenboer-Kuenen J, Morgenstern A, Bruchertseifer F, Heskamp S, Denkova AG. The in vivo fate of 225Ac daughter nuclides using polymersomes as a model carrier. Sci Rep. 2019;9:11671.","journal-title":"Sci Rep"},{"key":"3991_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-017-0667-1","volume":"37","author":"C Chalouni","year":"2018","unstructured":"Chalouni C, Doll S. Fate of antibody-drug conjugates in cancer cells. J Exp Clin Cancer Res. 2018;37:1\u201312.","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-03991-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-023-03991-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-03991-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T07:08:57Z","timestamp":1677222537000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-023-03991-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,24]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3991"],"URL":"https:\/\/doi.org\/10.1186\/s12967-023-03991-1","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,24]]},"assertion":[{"value":"11 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"144"}}